Skip to main content
. 2014 Sep 29;6(4):1953–1985. doi: 10.3390/cancers6041953

Table 1.

Phase II clinical trials measuring temozolomide efficacy in Glioblastoma.

Reference Response Study Population
Bower, et al. (1997) [29] 1 11% (CI 6%–24%) Progressive or recurrent high grade glioma
Brandes, et al. (2001) [30] 2 22.5% (CI 9.5%–35%) Recurrent high-grade glioma following surgery +RT and chemotherapy
Janinis, et al. (2000) [31] 1 25% (CI 12%–36%) Relapsing malignant glioma and poor performance status
Yung, et al. (2000) [32] 3 60% (p = 0.019) First relapse

Selected major studies reporting the clinical effect of temozolomide on glioblastoma. Response refers to major measure of response to therapy in each study. 1 Objective response rate. 2 Overall response rate. 3 6-month overall survival rate. CI = 95% Confidence Interval.